Medarex Licenses Protein Design Labs' Humanization Antibodies

Medarex, Inc. has licensed two bispecific antibody humanization patents from Protein Design Labs, Inc. (PDL). As well as non-refundable, non-creditable licensing and signing fees, Medarex will make milestone payments to PDL upon the achievement of clinical and regulatory objectives, pay annual maintenance fees and royalties on any sales that accrue from the licensed products.

PDL is a leader in the development of humanized antibodies to prevent or treat various disease conditions, such as autoimmune and inflammatory conditions, transplantation, cancer and viral infections. Three currently marketed therapeutic antibody products—PDL/Hoffmann-La Roche's Zenapax, Genentech's Herceptin and MedImmune's Synagis—are humanized and have been licensed under PDL's humanization patents.

For more information: Protein Design Labs, Inc., 2375 Garcia Ave., Mountain View, CA 94043, USA. Telephone: 415-903-3700.